Biliary

By Targets:	Antibiotic (3) Apical Sodium-Dependent Bile Acid Transporter (3) Bacterial (3) Biochemical Assay Reagents (1) Cytochrome P450 (2) Endogenous Metabolite (5) Fluorescent Dye (1) FXR (2) Parasite (1) Phosphatase (1) VEGFR (2)
By Research Areas:	Cancer (1) Endocrinology (2) Infection (4) Inflammation/Immunology (4) Metabolic Disease (8)

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-119412

Biliatresone	Others	Metabolic Disease
Biliatresone is a natural toxin isolated from Dysphania glomulifera and D. littoralis. Biliatresone, a 1,2-diaryl-2-propenone class of isoflavonoid, produces extrahepatic biliary atresia in a zebrafish model .

HY-W018512

7-Ketolithocholic acid 1 Publications Verification 3α-Hydroxy-7-oxo-5β-cholanic acid	Endogenous Metabolite	Metabolic Disease
7-Ketolithocholic acid (3α-Hydroxy-7-oxo-5β-cholanic acid), a bile acid, can be absorbed and suppresses endogenous bile acid production and biliary cholesterol secretion .

HY-114360

Taurohyodeoxycholic acid	Endogenous Metabolite	Metabolic Disease
Taurohyodeoxycholic acid is the tauroconjugated form of Hyodeoxycholic acid (HDCA, a dihydroxylated natural bile acid). Taurohyodeoxycholic acid induces a biliary phospholipid secretion and suggests a hepatoprotective potential. Taurohyodeoxycholic acid also can promote gallstone dissolution .

HY-109120

Odevixibat 2 Publications Verification A4250	Apical Sodium-Dependent Bile Acid Transporter	Metabolic Disease
Odevixibat (A4250) is a selective and orally active ileal apical sodium-dependent bile acid transporter (ASBT) inhibitor. Odevixibat decreases cholestatic liver and bile duct injury in mice model. Odevixibat has the potential for the treatment of primary biliary cirrhosis .

HY-B1210

Pipemidic acid	Bacterial Antibiotic	Infection
Pipemidic acid , a derivative of Piromidic acid, is an antibacterial agent. Pipemidic acid inhibits DNA gyrase. Pipemidic acid is active against gram-negative bacteria including Pseudomonas aeruginosa as well as some gram-positive bacteria. Pipemidic acid can be used for the research of intestinal, urinary, and biliary tract infections .

HY-16643

Linerixibat Maximum Cited Publications 10 Publications Verification GSK2330672	Apical Sodium-Dependent Bile Acid Transporter	Metabolic Disease Inflammation/Immunology
Linerixibat (GSK2330672) is a highly potent, nonabsorbable and orally active apical sodium-dependent bile acid transporter (ASBT) inhibitor with an IC₅₀ of 42 nM human ASBT. Linerixibat can be used as lipid-lowering agent. Linerixibat has the potential for type 2 diabetes and Primary Biliary Cholangitis treatment .

HY-W013766

Pipemidic acid trihydrate	Bacterial Antibiotic	Infection
Pipemidic acid trihydrate, a derivative of Piromidic acid, is an antibacterial agent. Pipemidic acid trihydrate inhibits DNA gyrase. Pipemidic acid trihydrate is active against gram-negative bacteria including Pseudomonas aeruginosa as well as some gram-positive bacteria. Pipemidic acid trihydrate can be used for the research of intestinal, urinary, and biliary tract infections .

HY-B2119

Sodium tauroglycocholate Tauroglycocholic acid sodium salt	Biochemical Assay Reagents	Endocrinology
Sodium tauroglycocholate is an inhibitor of the biliary acid transporting system of the hepatocyte and also a surfactant used as a chemical permeation enhancer.

HY-134988

EDP-305	FXR Phosphatase Cytochrome P450	Inflammation/Immunology
EDP-305 is an orally active, potent and selective farnesoid X receptor (FXR) agonist, with EC₅₀ values of 34 nM (chimeric FXR in CHO cells) and 8 nM (full-length FXR in HEK cells). EDP-305 shows a potent and consistent antifibrotic effect. EDP-305 can be used for primary biliary cholangitis (PBC) and non-alcoholic steatohepatitis (NASH) research .

HY-154857

1-Palmitoyl-2-succinyl-sn-glycerophosphorylcholine	Others	Cancer
1-Palmitoyl-2-succinyl-sn-glycerophosphorylcholine is a glycerophosphorylcholine, consisting of glycerol phosphate, choline and palmitic acid. It accumulates in vivo at sites of oxidative stress. 1-Palmitoyl-2-succinyl-sn-glycerophosphorylcholine may be a ligand of scavenger receptors class B, while oxidized phospholipids oxPC(CD36) are potent ligands of scavenger receptors class B (CD36 and SR-BI). Oxidized phospholipids (oxPLs) also play an important role in tumor apoptosis, may be elevated in malignant biliary strictures .

HY-B1043

Piromidic acid	Bacterial Antibiotic	Infection
Piromidic acid is an antibacterial agent. Piromidic acid is active against gramnegative bacteria and staphylococci and can be used for the research of intestinal, urinary, and biliary tract infections .

HY-N0545

Taurocholic acid sodium Maximum Cited Publications 10 Publications Verification Sodium taurocholate; N-Choloyltaurine sodium	VEGFR Endogenous Metabolite	Inflammation/Immunology
Taurocholic acid sodium (Sodium taurocholate) has marked bioactive effects such as an inhibitory potential against hepatic artery ligation induced biliary damage by upregulation of VEGF-A expression. Taurocholic acid sodium has immunoregulation effect .

HY-B1788

Taurocholic acid Maximum Cited Publications 10 Publications Verification N-Choloyltaurine
Taurocholic acid (N-Choloyltaurine) has marked bioactive effects such as an inhibitory potential against hepatic artery ligation induced biliary damage by upregulation of VEGF-A expression. Taurocholic acid has immunoregulation effect .

HY-119594

Melarsoprol Arsobal	Parasite	Infection
Melarsoprol (Arsobal), a melaminophenylarsine-type trivalent organic arsenical, is an important drug for African trypanosomiasis. Melarsoprol is also active against leukemia cell lines and plasma cells from myeloma patients. Melarsoprol increases the biliary output of GSH in rats .

HY-16747

Maralixibat chloride SHP625 chloride; LUM001 chloride; Lopixibat chloride	Apical Sodium-Dependent Bile Acid Transporter	Metabolic Disease
Maralixibat (SHP625) chloride is an orally active ileal bile acid transporter (IBAT) inhibitor. Maralixibat chloride can be used for the research of rare cholestatic liver diseases including Alagille syndrome (ALGS), progressive familial intrahepatic cholestasis (PFIC) and biliary atresia .

HY-N0545R

Taurocholic acid sodium (Standard) Sodium taurocholate (Standard); N-Choloyltaurine sodium (Standard)	VEGFR Endogenous Metabolite	Inflammation/Immunology
Taurocholic acid (sodium) (Standard) is the analytical standard of Taurocholic acid (sodium). This product is intended for research and analytical applications. Taurocholic acid sodium (Sodium taurocholate; N-Choloyltaurine sodium) has marked bioactive effects such as an inhibitory potential against hepatic artery ligation induced biliary damage by upregulation of VEGF-A expression. Immunoregulation effect .

HY-133707

β-Muricholic acid	Endogenous Metabolite	Metabolic Disease
β-Muricholic acid is a potent and orally active biliary cholesterol-desaturating agent. β-Muricholic acid prevents cholesterol gallstones. β-Muricholic acid inhibits lipid accumulation. β-Muricholic acid has the potential for the research of nonalcoholic fatty liver disease (NAFLD) .

HY-150787

BMS-986339	FXR Cytochrome P450	Metabolic Disease
BMS-986339 is an orally active, potent FXR agonist. BMS-986339 forms H-bond with His298 and ASN287 residues. BMS-986339 can be used in the research of primary biliary cirrhosis (PBC), primary sclerosing cholangitis (PSC), and nonalcoholic steatohepatitis (NASH), anti-fibrosis .

HY-113238F

FITC-Lithocholic acid 3-sulfate FITC-Sulfolithocholic acid	Fluorescent Dye	Others
FITC-Lithocholic acid 3-sulfate (FITC-Sulfolithocholic acid) is a FITC-labeled Lithocholic acid 3-sulfate, which is a sulfated biliary metabolite. Lithocholic acid 3-sulfate selectively inhibits Th17 cell differentiation by targeting RORγt. Lithocholic acid 3-sulfate can be used for the research of pathogenesis of cholestatic liver diseases .

Cat. No.	Product Name	Type

HY-113238F

FITC-Lithocholic acid 3-sulfate FITC-Sulfolithocholic acid	Fluorescent Dyes/Probes
FITC-Lithocholic acid 3-sulfate (FITC-Sulfolithocholic acid) is a FITC-labeled Lithocholic acid 3-sulfate, which is a sulfated biliary metabolite. Lithocholic acid 3-sulfate selectively inhibits Th17 cell differentiation by targeting RORγt. Lithocholic acid 3-sulfate can be used for the research of pathogenesis of cholestatic liver diseases .

Cat. No.	Product Name	Target	Research Area

HY-118534

Cyclobutyrol BRN-2209058	Peptides	Endocrinology
Cyclobutyrol is a potent choleretic agent. Cyclobutyrol also inhibits biliary lipid secretion. Cyclobutyrol induces choleretic is unrelated to bile acids. Cyclobutyrol and bile acids do not compete for the hepatobiliar transport mechanisms[1]

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-119412

Biliatresone	Structural Classification Flavonoids other families Classification of Application Fields Source classification Metabolic Disease Plants Disease Research Fields Isoflavones	Others
Biliatresone is a natural toxin isolated from Dysphania glomulifera and D. littoralis. Biliatresone, a 1,2-diaryl-2-propenone class of isoflavonoid, produces extrahepatic biliary atresia in a zebrafish model .

HY-W018512

7-Ketolithocholic acid 1 Publications Verification 3α-Hydroxy-7-oxo-5β-cholanic acid	Microorganisms Classification of Application Fields Source classification Metabolic Disease Endogenous metabolite Disease Research Fields Steroids	Endogenous Metabolite
7-Ketolithocholic acid (3α-Hydroxy-7-oxo-5β-cholanic acid), a bile acid, can be absorbed and suppresses endogenous bile acid production and biliary cholesterol secretion .

HY-114360

Taurohyodeoxycholic acid	Structural Classification Classification of Application Fields Source classification Metabolic Disease Endogenous metabolite Disease Research Fields Steroids	Endogenous Metabolite
Taurohyodeoxycholic acid is the tauroconjugated form of Hyodeoxycholic acid (HDCA, a dihydroxylated natural bile acid). Taurohyodeoxycholic acid induces a biliary phospholipid secretion and suggests a hepatoprotective potential. Taurohyodeoxycholic acid also can promote gallstone dissolution .

HY-B1043

Piromidic acid	Infection Structural Classification Classification of Application Fields Antibiotics Source classification Antibacterial Disease Research Endogenous metabolite Disease Research Fields Other Antibiotics	Bacterial Antibiotic
Piromidic acid is an antibacterial agent. Piromidic acid is active against gramnegative bacteria and staphylococci and can be used for the research of intestinal, urinary, and biliary tract infections .

HY-N0545

Taurocholic acid sodium Maximum Cited Publications 10 Publications Verification Sodium taurocholate; N-Choloyltaurine sodium	Structural Classification Classification of Application Fields Source classification Endogenous metabolite Inflammation/Immunology Disease Research Fields Steroids	VEGFR Endogenous Metabolite
Taurocholic acid sodium (Sodium taurocholate) has marked bioactive effects such as an inhibitory potential against hepatic artery ligation induced biliary damage by upregulation of VEGF-A expression. Taurocholic acid sodium has immunoregulation effect .

HY-N0545R

Taurocholic acid sodium (Standard) Sodium taurocholate (Standard); N-Choloyltaurine sodium (Standard)	Structural Classification Classification of Application Fields Source classification Endogenous metabolite Inflammation/Immunology Disease Research Fields Steroids	VEGFR Endogenous Metabolite
Taurocholic acid (sodium) (Standard) is the analytical standard of Taurocholic acid (sodium). This product is intended for research and analytical applications. Taurocholic acid sodium (Sodium taurocholate; N-Choloyltaurine sodium) has marked bioactive effects such as an inhibitory potential against hepatic artery ligation induced biliary damage by upregulation of VEGF-A expression. Immunoregulation effect .

HY-133707

β-Muricholic acid	Structural Classification Human Gut Microbiota Metabolites Microorganisms Classification of Application Fields Ketones, Aldehydes, Acids Source classification Metabolic Disease Endogenous metabolite Disease Research Fields	Endogenous Metabolite
β-Muricholic acid is a potent and orally active biliary cholesterol-desaturating agent. β-Muricholic acid prevents cholesterol gallstones. β-Muricholic acid inhibits lipid accumulation. β-Muricholic acid has the potential for the research of nonalcoholic fatty liver disease (NAFLD) .

Species:	Human (3)
Tag:	SUMO (1) His (2) Tag Free (1)
Source:	E. coli (3)

Cat. No.	Compare	Product Name	Species	Source

HY-P72129

	CEACAM1 Protein, Human Antigen CD66; BGP 1; BGP; BGP-1; BGPI; Biliary glycoprotein 1; Biliary glycoprotein adhesion molecule; Biliary glycoprotein; Carcinoembryonic antigen related cell adhesion molecule 1; carcinoembryonic antigen-related cell adhesion molecule 1 Biliary glycoprotein; ; Carcinoembryonic antigen-related cell adhesion molecule 1; CD66a; CD66a antigen; CEACAM1; CEAM1_HUMAN; meconium antigen 100	Human	E. coli
	CEACAM1 protein is involved in various biological processes. It is phosphorylated by the insulin receptor (INSR) in response to insulin stimulation, thereby promoting insulin clearance and regulating hepatic lipogenesis. CEACAM1 Protein, Human is the recombinant human-derived CEACAM1 protein, expressed by E. coli , with tag free. The total length of CEACAM1 Protein, Human is 394 a.a., with molecular weight of ~43.3 kDa.

HY-P72129A

	CEACAM1 Protein, Human (N-His) Antigen CD66; BGP 1; BGP; BGP-1; BGPI; Biliary glycoprotein 1; Biliary glycoprotein adhesion molecule; Biliary glycoprotein; Carcinoembryonic antigen related cell adhesion molecule 1; carcinoembryonic antigen-related cell adhesion molecule 1 Biliary glycoprotein; ; Carcinoembryonic antigen-related cell adhesion molecule 1; CD66a; CD66a antigen; CEACAM1; CEAM1_HUMAN; meconium antigen 100	Human	E. coli
	CEACAM1 protein is involved in various biological processes. It is phosphorylated by the insulin receptor (INSR) in response to insulin stimulation, thereby promoting insulin clearance and regulating hepatic lipogenesis. CEACAM1 Protein, Human (N-His) is the recombinant human-derived CEACAM1 protein, expressed by E. coli , with N-6*His labeled tag. The total length of CEACAM1 Protein, Human (N-His) is 394 a.a., with molecular weight of ~45 kDa.

HY-P72128

	CEACAM1 Protein, Human (His-SUMO) Antigen CD66; BGP 1; BGP; BGP-1; BGPI; Biliary glycoprotein 1; Biliary glycoprotein adhesion molecule; Biliary glycoprotein; Carcinoembryonic antigen related cell adhesion molecule 1; carcinoembryonic antigen-related cell adhesion molecule 1 Biliary glycoprotein; ; Carcinoembryonic antigen-related cell adhesion molecule 1; CD66a; CD66a antigen; CEACAM1; CEAM1_HUMAN; meconium antigen 100	Human	E. coli
	CEACAM1 protein is involved in various biological processes. It is phosphorylated by the insulin receptor (INSR) in response to insulin stimulation, thereby promoting insulin clearance and regulating hepatic lipogenesis. CEACAM1 Protein, Human (His-SUMO) is the recombinant human-derived CEACAM1 protein, expressed by E. coli , with N-10*His, N-SUMO labeled tag. The total length of CEACAM1 Protein, Human (His-SUMO) is 394 a.a., with molecular weight of ~63.3 kDa.


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inhibitors & Agonists

Fluorescent Dye

Peptides

Natural
Products

Recombinant Proteins

Biliary

Inhibitors & Agonists

Fluorescent Dye

Peptides

NaturalProducts

Recombinant Proteins

Natural
Products